Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,673 across all filing types
Latest filing 2023-10-12 Regulatory Filings
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment
Regulatory Filings Classification · 98% confidence The document is explicitly titled 'FORM 6-K' and is filed with the 'SECURITIES AND EXCHANGE COMMISSION' by a 'FOREIGN PRIVATE ISSUER'. Form 6-K is used by foreign private issuers to report material information that is required to be disclosed to shareholders pursuant to the laws of their home jurisdiction, or that is made public in their home jurisdiction, or that is required to be filed with any stock exchange on which their securities are traded. This type of filing is generally considered a miscellaneous regulatory filing that does not fit the specific definitions of 10-K (Annual Report), ER (Earnings Release), or IR (Interim Report). Since it is a mandatory SEC filing that doesn't match a more specific category like DEF 14A (Proxy/Remuneration) or DIRS (Insider Trading), the most appropriate general category for a non-standard SEC report from a foreign issuer is 'Regulatory Filings' (RNS), which serves as the fallback for miscellaneous regulatory announcements.
2023-10-12 English
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment
Report Publication Announcement Classification · 98% confidence The document is a short announcement (2065 characters) published on 12/10/2023, reporting the 'Closing of Exclusive License Agreement' and a 'Strategic Equity Investment'. It explicitly mentions being an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange, referencing a specific filing number. Crucially, the text states, 'Attached hereto is a report on...' and lists a PDF file name (*FORM_6-K_12-Oct-2023_isa.pdf*). According to the 'MENU VS MEAL' rule, a short announcement that points to an attached or linked report is classified as a Report Publication Announcement (RPA). While it contains material news, its function here is to announce the publication of the detailed report (likely a Form 6-K equivalent).
2023-10-12 English
6-K
Regulatory Filings
2023-09-28 English
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)
Regulatory Filings Classification · 98% confidence The document is explicitly titled 'FORM 6-K' and is filed with the 'SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is the standard filing for Foreign Private Issuers to report material information that is required to be publicly disclosed in their home country or stock exchange, or that is distributed to their shareholders. The content is a press release announcing 'Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial' for a drug candidate. This type of material, non-periodic disclosure by a foreign issuer is typically filed on Form 6-K. Since 'Form 6-K' is not one of the specific codes provided, the most appropriate fallback category for a general, material regulatory filing that doesn't fit the other specific categories (like 10-K, ER, or DIV) is 'Regulatory Filings' (RNS). The document length is substantial (14,626 chars), so it is the report/filing itself, not just an announcement of a report (RPA).
2023-09-28 English
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed under Regulation 4 of the Securities Regulations, specifically for a 'Foreign Corporation'. It announces encouraging clinical trial data and explicitly states, 'Attached hereto is a report on... *FORM_6-K_28-Sep-2023_isa.pdf*'. The document length is short (2036 characters) and its primary function is to announce the publication of an attached report (a Form 6-K, which is typically filed with the SEC for foreign private issuers, often relating to material events). According to Rule 2 ('THE "MENU VS MEAL" RULE'), if a document is short and states that a report is attached or published, it should be classified as a Report Publication Announcement (RPA) rather than the report itself. Since this is an announcement of a material event/report publication, RPA is the most appropriate classification.
2023-09-28 English
6-K
Regulatory Filings
2023-09-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.